Evotec SE (EVO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

EVO Stock Forecast


Evotec SE stock forecast is as follows: an average price target of $8.00 (represents a 133.24% upside from EVO’s last price of $3.43) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

EVO Price Target


The average price target for Evotec SE (EVO) is $8.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 133.24% upside from EVO's last price of $3.43.

EVO Analyst Ratings


Buy

According to 6 Wall Street analysts, Evotec SE's rating consensus is 'Buy'. The analyst rating breakdown for EVO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (50.00%), 2 'Hold' (33.33%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).

Evotec SE Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 15, 2024Douglas TsaoH.C. Wainwright$8.00$3.22148.45%133.24%
Apr 25, 2024Douglas TsaoH.C. Wainwright$11.00$5.23110.33%220.70%
Dec 09, 2022-H.C. Wainwright$12.00$8.3843.20%249.85%
Row per page
Go to

The latest Evotec SE stock forecast, released on Aug 15, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $8.00, which represents a 148.45% increase from the stock price at the time of the forecast ($3.22), and a 133.24% increase from EVO last price ($3.43).

Evotec SE Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$8.00$9.50
Last Closing Price$3.43$3.43$3.43
Upside/Downside-100.00%133.24%176.97%

In the current month, the average price target of Evotec SE stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evotec SE's last price of $3.43. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 15, 2024H.C. WainwrightBuyBuyHold
Aug 08, 2024Deutsche BankHoldSellDowngrade
Aug 07, 2024Oddo BHF-NeutralDowngrade
Jul 29, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Jul 11, 2024Deutsche BankBuyHoldDowngrade
Jun 28, 2024Cowen & Co.BuyBuyHold
Apr 25, 2024H.C. WainwrightBuyBuyHold
Apr 12, 2024Deutsche BankHoldBuyUpgrade
Aug 31, 2023CitigroupBuyBuyHold
Jun 23, 2023Morgan Stanley-OverweightUpgrade
Row per page
Go to

Evotec SE's last stock rating was published by H.C. Wainwright on Aug 15, 2024. The company gave EVO a "Buy" rating, the same as its previous rate.

Evotec SE Financial Forecast


Evotec SE Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Revenue------------$240.69M$173.88M$172.20M$164.67M$187.07M$133.09M$140.51M$129.43M$111.59M$119.40M$125.08M$114.27M$103.24M
Avg Forecast$250.38M$244.09M$271.24M$270.91M$247.87M$225.42M$220.08M$210.52M$210.06M$190.79M$198.27M$217.53M$178.45M$178.15M$163.99M$173.14M$182.96M$137.76M$137.46M$128.42M$146.42M$126.17M$119.65M$114.04M$103.15M
High Forecast$250.38M$244.09M$271.24M$270.91M$247.87M$246.32M$220.08M$210.52M$222.93M$190.79M$198.27M$217.53M$178.45M$178.15M$163.99M$173.14M$182.96M$137.76M$137.46M$128.42M$146.42M$126.17M$119.65M$114.04M$103.15M
Low Forecast$250.38M$244.09M$271.24M$270.91M$247.87M$198.23M$220.08M$210.52M$197.17M$190.79M$198.27M$217.53M$178.45M$178.15M$163.99M$173.14M$182.96M$137.76M$137.46M$128.42M$146.42M$126.17M$119.65M$114.04M$103.15M
# Analysts----12112111----111111---
Surprise %------------1.35%0.98%1.05%0.95%1.02%0.97%1.02%1.01%0.76%0.95%1.05%1.00%1.00%

Evotec SE's average Quarter revenue forecast for Mar 23 based on 1 analysts is $217.53M, with a low forecast of $217.53M, and a high forecast of $217.53M. EVO's average Quarter revenue forecast represents a -9.62% decrease compared to the company's last Quarter revenue of $240.69M (Dec 22).

Evotec SE EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts----12112111----111111---
EBITDA------------$35.65M$-14.16M$-6.50M$60.31M$-14.82M$56.75M$6.46M$8.87M$-4.41M$26.77M$16.01M$26.65M$3.77M
Avg Forecast$37.05M$36.12M$40.13M$40.08M$36.68M$33.35M$32.56M$31.15M$31.08M$28.23M$29.34M$32.19M$26.40M$26.36M$24.26M$-75.35M$36.64M$27.59M$27.53M$25.72M$29.33M$25.27M$23.96M$22.84M$20.66M
High Forecast$37.05M$36.12M$40.13M$40.08M$36.68M$36.45M$32.56M$31.15M$32.99M$28.23M$29.34M$32.19M$26.40M$26.36M$24.26M$-60.28M$36.64M$27.59M$27.53M$25.72M$29.33M$25.27M$23.96M$22.84M$20.66M
Low Forecast$37.05M$36.12M$40.13M$40.08M$36.68M$29.33M$32.56M$31.15M$29.17M$28.23M$29.34M$32.19M$26.40M$26.36M$24.26M$-90.42M$36.64M$27.59M$27.53M$25.72M$29.33M$25.27M$23.96M$22.84M$20.66M
Surprise %------------1.35%-0.54%-0.27%-0.80%-0.40%2.06%0.23%0.35%-0.15%1.06%0.67%1.17%0.18%

1 analysts predict EVO's average Quarter EBITDA for Mar 23 to be $32.19M, with a high of $32.19M and a low of $32.19M. This is -9.72% lower than Evotec SE's previous annual EBITDA (Dec 22) of $35.65M.

Evotec SE Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts----12112111----111111---
Net Income------------$-27.20M$-47.27M$-27.94M$-73.24M$-31.48M$52.70M$403.00K$-1.41M$-9.82M$22.23M$8.36M$19.05M$-2.39M
Avg Forecast$1.79M$1.79M$5.36M$1.79M$1.77M$-3.80M$-6.32M$-4.22M$-4.83M$-4.83M$-9.83M$14.33M$-1.33M$-15.02M$5.49M$-85.45M$622.02M$5.36M$5.15M$900.51K$17.29M$8.51M$14.01M$18.11M$13.54M
High Forecast$1.79M$1.79M$5.36M$1.79M$1.77M$633.67K$-6.32M$-4.22M$1.61M$-4.83M$-9.83M$14.33M$-1.33M$-15.02M$5.49M$-68.36M$622.02M$5.36M$5.15M$900.51K$17.29M$8.51M$14.01M$18.11M$13.54M
Low Forecast$1.79M$1.79M$5.36M$1.79M$1.77M$-8.87M$-6.32M$-4.22M$-11.28M$-4.83M$-9.83M$14.33M$-1.33M$-15.02M$5.49M$-102.54M$622.02M$5.36M$5.15M$900.51K$17.29M$8.51M$14.01M$18.11M$13.54M
Surprise %------------20.49%3.15%-5.09%0.86%-0.05%9.84%0.08%-1.57%-0.57%2.61%0.60%1.05%-0.18%

Evotec SE's average Quarter net income forecast for Dec 21 is $622.02M, with a range of $622.02M to $622.02M. EVO's average Quarter net income forecast represents a 1080.25% increase compared to the company's last Quarter net income of $52.70M (Mar 21).

Evotec SE SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts----12112111----111111---
SG&A------------$46.33M$42.46M$35.83M$31.57M$34.41M$21.19M$19.11M$21.60M$19.28M$17.25M$20.32M$16.32M$15.14M
Avg Forecast$45.01M$43.88M$48.76M$48.70M$44.56M$40.52M$39.56M$37.84M$37.76M$34.30M$35.64M$39.10M$32.08M$32.02M$29.48M$36.83M$30.50M$22.97M$22.92M$21.41M$24.41M$21.03M$19.95M$19.01M$17.20M
High Forecast$45.01M$43.88M$48.76M$48.70M$44.56M$44.28M$39.56M$37.84M$40.07M$34.30M$35.64M$39.10M$32.08M$32.02M$29.48M$44.19M$30.50M$22.97M$22.92M$21.41M$24.41M$21.03M$19.95M$19.01M$17.20M
Low Forecast$45.01M$43.88M$48.76M$48.70M$44.56M$35.63M$39.56M$37.84M$35.44M$34.30M$35.64M$39.10M$32.08M$32.02M$29.48M$29.46M$30.50M$22.97M$22.92M$21.41M$24.41M$21.03M$19.95M$19.01M$17.20M
Surprise %------------1.44%1.33%1.22%0.86%1.13%0.92%0.83%1.01%0.79%0.82%1.02%0.86%0.88%

Evotec SE's average Quarter SG&A projection for Mar 23 is $39.10M, based on 1 Wall Street analysts, with a range of $39.10M to $39.10M. The forecast indicates a -15.61% fall compared to EVO last annual SG&A of $46.33M (Dec 22).

Evotec SE EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts----12112111----111111---
EPS------------$-0.08$-0.13$-0.08$-0.21$-0.09$0.16-$-0.01$-0.04$0.06$0.03$0.07$-0.01
Avg Forecast$0.01$0.01$0.03$0.01$0.01$-0.02$-0.04$-0.02$-0.03$-0.03$-0.06$0.08$-0.01$-0.08$0.03$0.06$1.76$0.02$0.01-$0.05$0.02$0.04$0.05$0.04
High Forecast$0.01$0.01$0.03$0.01$0.01-$-0.04$-0.02$0.01$-0.03$-0.06$0.08$-0.01$-0.08$0.03$0.06$1.76$0.02$0.01-$0.05$0.02$0.04$0.05$0.04
Low Forecast$0.01$0.01$0.03$0.01$0.01$-0.05$-0.04$-0.02$-0.06$-0.03$-0.06$0.08$-0.01$-0.08$0.03$0.06$1.76$0.02$0.01-$0.05$0.02$0.04$0.05$0.04
Surprise %------------10.29%1.53%-2.56%-3.56%-0.05%10.57%0.09%-1.96%-0.72%2.29%0.70%1.27%-0.26%

According to 1 Wall Street analysts, Evotec SE's projected average Quarter EPS for Dec 21 is $1.76, with a low estimate of $1.76 and a high estimate of $1.76. This represents a 998.59% increase compared to EVO previous annual EPS of $0.16 (Mar 21).

Evotec SE Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PCRXPacira BioSciences$16.52$40.00142.13%Hold
EVOEvotec SE$3.43$8.00133.24%Buy
ANIPANI Pharmaceuticals$57.83$79.0036.61%Buy
NBIXNeurocrine Biosciences$114.00$146.6028.60%Buy
PBHPrestige Consumer Healthcare$68.83$82.0019.13%Buy
SUPNSupernus Pharmaceuticals$32.02$38.0018.68%Buy
DCPHDeciphera Pharmaceuticals$25.59$26.322.85%Hold
COLLCollegium Pharmaceutical$41.86$41.50-0.86%Buy
PAHCPhibro Animal Health$21.31$18.67-12.39%Buy

EVO Forecast FAQ


Yes, according to 6 Wall Street analysts, Evotec SE (EVO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 50.00% of EVO's total ratings.

Evotec SE (EVO) average price target is $8 with a range of $8 to $8, implying a 133.24% from its last price of $3.43. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for EVO stock, the company can go up by 133.24% (from the last price of $3.43 to the average price target of $8), up by 133.24% based on the highest stock price target, and up by 133.24% based on the lowest stock price target.

EVO's average twelve months analyst stock price target of $8 supports the claim that Evotec SE can reach $5 in the near future.

Evotec SE's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $903.9M (high $924.79M, low $876.71M), average EBITDA is $133.74M (high $136.84M, low $129.72M), average net income is $-12.561M (high $-8.126M, low $-17.631M), average SG&A $162.48M (high $166.23M, low $157.59M), and average EPS is $-0.0708 (high $-0.0458, low $-0.0994). EVO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.04B (high $1.04B, low $1.04B), average EBITDA is $153.38M (high $153.38M, low $153.38M), average net income is $10.73M (high $10.73M, low $10.73M), average SG&A $186.34M (high $186.34M, low $186.34M), and average EPS is $0.0605 (high $0.0605, low $0.0605).

Based on Evotec SE's last annual report (Dec 2022), the company's revenue was $751.45M, beating the average analysts forecast of $693.72M by 8.32%. Apple's EBITDA was $94.15M, beating the average prediction of $1.68M by 5503.49%. The company's net income was $-176M, beating the average estimation of $-96.314M by 82.38%. Apple's SG&A was $156.19M, beating the average forecast of $130.4M by 19.77%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.00223 by 22275.87%. In terms of the last quarterly report (Dec 2022), Evotec SE's revenue was $240.69M, beating the average analysts' forecast of $178.45M by 34.88%. The company's EBITDA was $35.65M, beating the average prediction of $26.4M by 35.02%. Evotec SE's net income was $-27.201M, beating the average estimation of $-1.327M by 1949.30%. The company's SG&A was $46.33M, beating the average forecast of $32.08M by 44.44%. Lastly, the company's EPS was $-0.077, beating the average prediction of $-0.00749 by 928.56%